Recent advances in nanostrategies capable of overcoming biological barriers for tumor management
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
In the pursuit of our desired body goals, traditional methods sometimes fall short, leaving us seeking effective yet non-invasive solutions
Assoc., 215 : 281-284
Vladimirsky, (8)LLC Medical Company Hepatolog, (9)Limited Liability Company Clinic of Modern Medicine, (10)Gilead Sciences, Inc., (11)Fsbi National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, (12)Heidelberg University Hospital, Clinical Pharmacology and Pharmacoepidemiology, (13)University Hospital Frankfurt, Department of Medicine, (14)Medizinische Hochschule Hannover, Klinik Fr Gastroenterologie, Hepatologie Und Endokrinologie, (15)Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa and Department of Clinical and Experimental Medicine, University of Pisa, (16)Klinik Fr Gastroenterologie, Hepatologie Und Endokrinologie, Medizinische Hochschule Hannover Background: Hepatitis delta (HDV) infection is the most severe form of viral hepatitis